Literature DB >> 7612231

Superantigens of mouse mammary tumor virus.

H Acha-Orbea1, H R MacDonald.   

Abstract

Superantigens (SAgs) are proteins of microbial origin that bind to major histocompatibility complex (MHC) class II molecules and stimulate T cells via interaction with the V beta domain of the T cell receptor (TCR). Mouse mammary tumor virus (MMTV) is a milk-transmitted type B retrovirus that encodes a SAg in its 3' long terminal repeat. Upon MMTV infection, B cells present SAg to the appropriate T cell subset, which leads to a strong "cognate" T-B interaction. This immune reaction results in preferential clonal expansion of infected B cells and differentiation of some of these cells into long-lived memory cells. In this way a stable MMTV infection is achieved that ultimately results in infection of the mammary gland and virus transmission via milk. Thus, in contrast to many microorganisms that attempt to evade the host immune system (reviewed in 1), MMTV depends upon a strong SAg-induced immune response for its survival. Because of their ability to stimulate very strong T cell responses in MHC-identical mice, minor lymphocyte stimulatory (Mls) antigens, discovered more than 20 years ago, are now known to be SAgs encoded by endogenous MMTV proviruses that have randomly integrated into germ cells. The aim of this review is to combine the extensive biology of Mls SAgs with our current understanding of the life cycle of MMTV.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7612231     DOI: 10.1146/annurev.iy.13.040195.002331

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  64 in total

1.  Alternative proteolytic processing of mouse mammary tumor virus superantigens.

Authors:  F Denis; N H Shoukry; M Delcourt; J Thibodeau; N Labrecque; H McGrath; J S Munzer; N G Seidah; R P Sékaly
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Induction of transplantation tolerance to fully mismatched cardiac allografts by T cell mediated delivery of alloantigen.

Authors:  Chaorui Tian; Xueli Yuan; Peter T Jindra; Jessamyn Bagley; Mohamed H Sayegh; John Iacomini
Journal:  Clin Immunol       Date:  2010-05-08       Impact factor: 3.969

3.  The mouse mammary tumor virus transcription enhancers for hematopoietic progenitor and mammary gland cells share functional elements.

Authors:  F U Reuss; J M Coffin
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Both T and B cells shed infectious mouse mammary tumor virus.

Authors:  J L Dzuris; T V Golovkina; S R Ross
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

5.  DBA/2J (Mls-1a) B-cell differentiation in BALB.xid recipients.

Authors:  K Tocce; K Suppiah; C Rago; R Liberchuk; K Duffy; J Riggs
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 6.  Bacterial superantigens.

Authors:  T Proft; J D Fraser
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

7.  Requirement of full TCR repertoire for regulatory T cells to maintain intestinal homeostasis.

Authors:  Junko Nishio; Minato Baba; Koji Atarashi; Takeshi Tanoue; Hideo Negishi; Hideyuki Yanai; Sonoko Habu; Shohei Hori; Kenya Honda; Tadatsugu Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-29       Impact factor: 11.205

8.  Retrovirus-induced target cell activation in the early phases of infection: the mouse mammary tumor virus model.

Authors:  C Ardavin; F Luthi; M Andersson; L Scarpellino; P Martin; H Diggelmann; H Acha-Orbea
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

9.  Fumonisin and beauvericin induce apoptosis in turkey peripheral blood lymphocytes.

Authors:  Mary Ann Dombrink-Kurtzman
Journal:  Mycopathologia       Date:  2003       Impact factor: 2.574

10.  Mouse mammary tumor virus superantigen expression in B cells is regulated by a central enhancer within the pol gene.

Authors:  F U Reuss; J M Coffin
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.